

**mini**



**Park Hyatt Toronto**

**Program at a Glance**

	Saturday February 6	Sunday February 7
7am – 8am	<i>Breakfast</i>	<i>Breakfast</i>
8:00am-9:45am	Session 1 Current Issues in Infectious Disease, and New Evidence for Management of Scalp Psoriasis among Various Racial Backgrounds	Session 5 Update and Current Issues in Acne
9:45am-10:00am	<i>Coffee Break</i>	<i>Coffee Break</i>
10:00am – 11:45am	Session 2 A New Optimized Treatment for Actinic Keratosis	Session 6 Pso and PsA in a Biologic Era: Safety Considerations and Treatment Decisions
11:45am – 12:45pm	<i>Lunch</i>	<i>Lunch</i>
12:45pm – 2:30pm	Session 3 Literature Update on Atopic Dermatitis, Skin Barrier Effect and the Filaggrin Story	Session 7 General Session
2:30pm – 2:45pm	<i>Coffee Break</i>	
2:45pm – 4:30pm	Session 4 Understanding your Male Patients: Grooming Issues you want to know about	

**Conference Sponsors**



**mini**



**Park Hyatt Toronto**

**Saturday, February 6, 2010**

**8:00 – 9:45am**

**Session 1**

**Current Issues in Infectious Disease, and New Evidence for Management of Scalp Psoriasis among Various Racial Backgrounds.**

**Overall Learning Objectives**

- a) Provide a primer on best practices to control infection in your office
- b) Provide recent results from a 52 week study of the two compound scalp gel in the management of scalp psoriasis in people of various racial backgrounds.

At the end of the conference, the participants will be able to:

- i. Understand the different processes of sterilization and disinfection.
- ii. Understand the different types of patients isolation.
- iii. Implement a global quality assurance program in terms of infection control.
- iv. Understand the study design and results.
- v. Be able to apply study evidence to managing scalp psoriasis in their clinical practice.

**Agenda**

8:00 – 8:40	Infection Control in Your Office - <i>Dr. Karl Weiss</i>
8:40 – 8:45	Questions
8:45 – 9:25	New Evidence for Management of Scalp Psoriasis among Various Racial Backgrounds – <i>Dr. Richard Thomas</i>
9:25 – 9:30	Questions
9:30 – 9:45	General Discussion

**Session Faculty**

Dr. Karl Weiss, MD, MSc, FRCPC, Professor of Medicine, Maisonneuve-Rosemont Hospital, Faculty of Medicine, Université de Montréal, Co-chair of the Infection Control Board for Montreal, Montreal, QC

Dr. Richard Thomas, MD, FRCP(C), Assistant Clinical Professor, Department of Dermatology & Skin Science, University of British Columbia, Vancouver, BC

**Conference Sponsors**



**mini**



**Park Hyatt Toronto**

Saturday, February 6, 2010

10:00 – 11:45am

Session 2

A New Optimized Treatment for Actinic Keratosis

Overall Learning Objectives

To expose the Canadian dermatology community to an optimized therapy for the treatment of Actinic Keratosis

Agenda

10:00 – 10:15 Introductions and the Importance of Field Therapy for Actinic Keratosis - *Dr. Chih-ho Hong*

10:15 – 10:45 Imiquimod: history, mode of action and the rationale for the development of a new concentration –  
*Dr. Dick Miller*

10:45 – 11:30 New optimized therapy for the treatment of Actinic Keratosis - *Dr. Ted Rosen*

11:30 – 11:45 Panel Q&A

Session Faculty

Dr. Chih-ho Hong, Clinical Assistant Professor, Department of Dermatology & Skin Science, University of British Columbia, Diplomate, American Board of Dermatology, St. Paul's Hospital, Vancouver, BC

Dr. Richard L. Miller, retired Corporate Scientist, 3M Pharmaceuticals, 3M Company, Maplewood, MN

Dr. Ted Rosen, Chief of the VA Dermatology Clinic, Professor, Department of Dermatology, Baylor College of Medicine, Houston, TX, USA

Conference Sponsors



**mini**



**Park Hyatt Toronto**

Saturday, February 6, 2010

12:45 – 2:30pm

Session 3

Literature Update on Atopic Dermatitis, Skin Barrier Effect and the Filaggrin Story

Overall Learning Objectives

- Update on latest literature relating to atopic dermatitis (AD)
- Examine GAPS in practice vs. literature
- AD in sensitive skin and the role of skin barrier
- Innovation of skin care treatment options

Agenda

- 12:45 – 1:15 A review of evidence based literature to determine the safety and efficacy profiles of topical steroids (TCSs) and topical calcineurin inhibitors (TCIs) and their use in atopic dermatitis and to examine the current management and treatment practices advocated for atopic dermatitis – *Dr. Ron Vender*
- 1:15 – 1:45 Managing atopic dermatitis in sensitive skin: a closer look at skin barrier integrity and innate immunity - *Dr. Mani Raman*
- 1:45 – 2:15 Understanding the role of the skin barrier in atopic dermatitis for innovation in therapeutic skin care – *Dr. Eric Simpson*
- 2:15 – 2:30 Q and A with Faculty

Session Faculty

Dr. Mani Raman, The Centre for Dermatology & Cosmetic Surgery

Ron Vender, MD, FRCPC, Director of Dermaterials Research, Hamilton, ON

Dr. Eric Simpson, Associate Professor, Dermatology, Oregon Health & Science University

Conference Sponsors



**mini**



**Park Hyatt Toronto**

Saturday, February 6, 2010

2:45 – 4:30pm

Session 4

Understanding your Male Patients: Grooming Issues you want to know about

Overall Learning Objectives

Provide Insights into the unique needs of male patients and shaving.

Attendees will learn about research behind men's behaviours & practices, physiologies as well as technical measures that assess shaving product performance. Clinical data for optimal shaving regimen will be discussed.

Agenda

2:45 – 2:55 Welcome & Introduction - *Stefani Valkonen*

2:55 – 4:15 Understanding your Male Patients-Grooming Issues you want to know about – *Pam Zupkosky*

4:15 – 4:30 Question and Answers – *Pam Zupkosky*

Session Faculty

Stefani Valkonen-, P&G External Relations Director

Pam Zupkosky, P&G Global Grooming R&D

Conference Sponsors



**mini**



**Park Hyatt Toronto**

**Sunday, February 7, 2010**

**8:00 – 9:45am**

**Session 5**

**Update and Current Issues in Acne**

**Overall Learning Objectives**

1. To present new developments in the basic science and clinical research of acne.
2. To evaluate the credibility of recent concerns regarding the use of systemic agents in acne.
3. To discuss the effect of resistant P. acnes on the role of antibiotics in acne.

**Agenda**

- 8:00 - 8:30 New treatments in trials - eg, phototherapy, PDT, others - *Dr. Jerry Tan*
- 8:30 - 9:00 Concerns re: oral isotretinoin - GI studies - *Dr. Bill Danby*
- 9:00 - 9:20 Antibiotics in acne - *Dr. Maha Dutil*
- 9:20 - 9:30 Hormonal aspects of acne - including OC therapy and risks - *Dr. Jerry Tan and Dr. Bill Danby*
- 9:30 – 9:45 Questions and Panel Discussion

**Session Faculty**

Dr. Bill Danby, Private Practice, Manchester, NH, Adjunct Assistant Professor of Medicine (Dermatology), Dartmouth Medical School, Hanover, NH

Dr. Maha Dutil, Maha Dutil M.D. M.Ed. FRCP(C), Assistant Professor of Medicine, Division of Dermatology, University of Toronto, Women's College Hospital, Private Practice Toronto, ON

Dr. Jerry Tan, Adjunct Professor, University of Western Ontario, Windsor Regional Hospital, Private Practice, General Dermatology, Windsor, ON

**Conference Sponsors**



**mini**



**Park Hyatt Toronto**

**Sunday, February 7, 2010**

**10:00 – 11:45am**

**Session 6**

**Pso and PsA in a Biologic Era: Safety Considerations and Treatment Decisions**

**Overall Learning Objectives**

- 1) Cite the data regarding the use of biological and conventional therapy for the treatment of psoriasis (competence) and identify certain patient scenarios whereby there may be an increased benefit by using a biologic versus conventional therapy (patient outcomes)
- 2) Recognize co-morbidities that often exist in the context of psoriasis patients (competence) and develop appropriate management strategies in order to improve healthcare outcomes for your patients (performance/patient outcomes)
- 3) Review the data for contraindications in psoriasis treatment (competence) and identify clinical cases where this data applies (performance)
- 4) Identify co-existing clinical states that associated with psoriasis that may complicate the choice of effective therapy (competence) and implement therapy based on the most current evidence-based studies applicable to the specific setting (performance).
- 5) Understand how to interpret data from RCTs and world registry data for biologics and review the long term safety data for anti-TNF biologics

**Agenda**

10:00 – 10:05 Opening Chairperson Remarks - *Dr. Lyn Guenther*

10:05 – 10:35 Biologics: Summary of Clinical Trials - *Dr. Lyn Guenther*

10:35 – 11:35 Real World Cases in Psoriasis and Psoriatic Arthritis: Treatment Decisions Reached in a Multidisciplinary Clinic and Validation by a *post hoc* Delphi Consensus Exercise - *Dr. Bruce Strober*  
**Needs:**

There is a large demand for dermatologists to be competent in the diagnosis and treatment of moderate to severe psoriasis. Specifically, fewer dermatologists are able to utilize the full range of therapeutics, both new and old, for moderate to severe psoriasis, and subsequently are less able to positively alter the lives of patients with this devastating disease.

Often, psoriasis patients suffer from co-morbid conditions that preclude the use of certain therapies, or simply direct therapy towards a more appropriate choice. Dermatologists must be familiar in the limited data that support treatment choices in these settings.

11:35 – 11:45 Q & A Opportunity - *Dr. Lyn Guenther & Dr. Bruce Strober*

**Session Faculty**

Dr. Bruce Strober, Assistant Professor and Director, Dermatopharmacology Unit, New York University School of Medicine, Ronald O. Perelman Department of Dermatology, New York University Medical Center, New York, NY

Dr. Lyn Guenther, Professor, Division of Dermatology, University of Western Ontario, Medical Director Guenther Dermatology Research Centre, London, ON

**Conference Sponsors**



**mini**



**Park Hyatt Toronto**

Sunday, February 7, 2010

12:45 – 2:30am

Session 7

- 12:45 – 1:15    Drugs for the Management of Skin Disease 2010  
*Dr. Stuart Maddin*
- 1:15 – 1:45    Bash-the-doctor websites like [www.ratemds.com](http://www.ratemds.com): you WILL get bashed!  
How to deal with it.  
What to do.  
What NOT to do.  
How to get ahead of the problem!  
*Dr. Kevin Smith*
- 1:45 – 2:15    Clinical Trials – An Overview  
*Dr. Paul Kidson*
- 2:15 – 2:25    Q&A with the Faculty
- 2:25 – 2:30    Closing Comments  
*Dr. Stuart Maddin*

Session Faculty

Dr. Paul Kidson, DVM, VP Health Outcomes, LEO Pharma, Mississauga, ON

Dr. Stuart Maddin, Professor Emeritus, Department of Dermatology & Skin Science, University of British Columbia Vancouver, BC

Dr. Kevin Smith, Niagara Falls Dermatology & Skin Care Centre, Ltd., Niagara Falls, ON

Conference Sponsors

